N-2-(1,3-Dihydroxy-2-methylpropyl)-acetamid | 66671-83-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-2-(1,3-Dihydroxy-2-methylpropyl)-acetamid
• 英文别名: N-(2-hydroxy-1-hydroxymethyl-1-methyl-ethyl)-acetamide；N-(2-Hydroxy-1-hydroxymethyl-1-methyl-aethyl)-acetamid；2-Acetylamino-2-methyl-propan-1,3-diol；N-2-(1,3-Dihydroxy-2-methylpropyl) acetamide；N-(1,3-dihydroxy-2-methylpropan-2-yl)acetamide
• CAS: 66671-83-8
• 化学式: C₆H₁₃NO₃
• 分子量: 147.174
• InChiKey: XFACEAHMBQFBTP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.6
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  69.6
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  2-acetamido-1,3-diacetoxy-2-methylpropane 在 barium dihydroxide 、 水 作用下， 生成 N-2-(1,3-Dihydroxy-2-methylpropyl)-acetamid
  参考文献：
  名称：

  Nys; Libeer, Bulletin des Societes Chimiques Belges, 1956, vol. 65, p. 377,383

  摘要：

  DOI：

文献信息

• Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US20150231142A1

  公开（公告）日：2015-08-20

  The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

  本发明涉及含有上皮钠通道活性抑制剂与至少一种ABC转运蛋白调节剂化合物（A式、B式、C式或D式）的药物组合物。该发明还涉及这些药物配方，以及使用这些组合物治疗CFTR介导的疾病，特别是囊性纤维化的方法。
• COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES
  申请人：Van Goor Fredrick F.

  公开号：US20110098311A1

  公开（公告）日：2011-04-28

  The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

  本发明涉及包含上皮钠通道活性抑制剂与至少一种ABC转运蛋白调节剂化合物（A式、B式、C式或D式）的药物组合物。该发明还涉及这些药物配方，以及使用这些组合物治疗CFTR介导的疾病，特别是囊性纤维化的方法。
• [EN] METHOD OF MAKING A COMPOSITION OF AN ALKANOLAMINE ALKYLAMIDE AND A POLYOL<br/>[FR] PROCÉDÉ DE PRODUCTION D'UNE COMPOSITION D'UN ALCANOLAMINE ALKYLAMIDE ET D'UN POLYOL
  申请人：AKZO NOBEL CHEMICALS INT BV

  公开号：WO2017129272A1

  公开（公告）日：2017-08-03

  The disclosure generally provides methods for preparing compositions comprising alkanolamine alkylamides and polyols. This disclosure further relates to methods for preparing compositions comprising alkanolamine alkylamides and polyols that can be used in formulations that provide moisturization.

  该披露通常提供了制备含有醇胺烷基酰胺和多元醇的组合物的方法。该披露还涉及制备含有醇胺烷基酰胺和多元醇的组合物的方法，这些组合物可以用于提供保湿效果的配方中。
• [EN] PHOTOINITATORS<br/>[FR] PHOTOINITATEURS
  申请人：COLOPLAST AS

  公开号：WO2018095495A1

  公开（公告）日：2018-05-31

  A photoinitiator is provided which incorporates a camphorquinone photoinitiator moiety.

  提供了一种包含藿香酮光引发剂基团的光引发剂。
• RING-FUSED HETEROCYCLIC DERIVATIVE
  申请人：Sawada Takashi

  公开号：US20140038941A1

  公开（公告）日：2014-02-06

  A ring-fused heterocyclic derivative represented by the following general formula (I) or a pharmaceutically acceptable salt thereof having a T-type calcium channel regulatory effect and useful as a pruritus therapeutic and/or preventive agent, and the like are provided. In the general formula (I), R 1 represents optionally substituted lower alkyl, and the like; R 2 represents an optionally substituted cycloalkyl, and the like; Q represents a hydrogen atom, and the like; R 3 represents —C(═O)NR 8 R 9 (wherein R 8 and R 9 may be the same or different, and each represents a hydrogen atom, and the like), and the like; L 1 represents —CR 11A R 11B — (wherein R 11A and R 11B may be the same or different, and each represents a hydrogen atom, and the like), and the like; and W 1 and W 2 may be the same or different, and each represents C—R 12 (wherein R 12 represents a hydrogen atom, and the like), and the like.

  提供一种由以下一般式(I)表示的环融合杂环衍生物或其药学上可接受的盐，具有T型钙通道调节作用，可用作瘙痒治疗和/或预防剂等。在一般式(I)中，R1表示可选取代的低碳基等；R2表示可选取代的环烷基等；Q表示氢原子等；R3表示-C（═O）NR8R9（其中R8和R9可以相同或不同，且每个表示氢原子等）等；L1表示-CR11AR11B-（其中R11A和R11B可以相同或不同，且每个表示氢原子等）等；W1和W2可以相同或不同，且每个表示C-R12（其中R12表示氢原子等）等。

表征谱图